Cadrenal Therapeutics CVKD
NASDAQ CVKD
$1.39 -0.05 (-3.16%)
As of: Nov 11, 2026 · 12:13 PM EST

Cadrenal Therapeutics (CVKD) Non Operating Interest Expenses (2022 - 2023)

Updated

Cadrenal Therapeutics (CVKD) recorded Non Operating Interest Expenses of $3,534 in Q1 2023, up 69.8% from $2,081 a year earlier but down 80.5% from the prior quarter.

Analysis

Cadrenal Therapeutics (CVKD) Non Operating Interest Expenses (2022 - 2023) Analysis & Trends

For FY2022, Cadrenal Therapeutics reported Non Operating Interest Expenses of $40,192.

  • Quarterly Non Operating Interest Expenses has ranged from $2,081 in Q1 2022 to $18,104 in Q4 2022 over the past five years.
  • Per Business Quant, the preceding three quarters came in at $18,104 (Q4 2022), $13,544 (Q3 2022) and $6,446 (Q2 2022).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Operating Interest Expenses (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn -
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn 217.00 Mn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn -
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn -
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn -477.00 Mn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn 653.00 Mn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn 269.00 Mn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn -
10 Cadrenal Therapeutics 557,746.58 -12.06 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2023 3,534.00
Dec 31, 2022 18,104.00
Sep 30, 2022 13,544.00
Jun 30, 2022 6,446.00
Mar 31, 2022 2,081.00
API Access

Cadrenal Therapeutics Non Operating Interest Expenses API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=non-operating-interest-expenses&ticker=CVKD&period=max&api_key=YOUR_API_KEY